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Abstract
I In nt tr ro od du uc ct ti io on n: : TGF-β1 is a cytokine with many different effects on cell proliferation,
differentiation and inflammation and can protect against the development of
COPD. This work aims to study the association between COPD and the TGF-β1
gene genotypes.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   The study included 70 males: 25 smokers with COPD, 
25 resistant smokers, and 20 normal non-smokers as the control. They were
subjected to spirometry pre- and post-bronchodilator (FEV1, FEV1/FVC), estimation
of serum level of TGF-β1 gene by PCR and RFLP.
R Re es su ul lt ts s: :   The percent of Pro-Leu was 28% in the COPD group, 84% in the resistant
smokers group and 85% in the control group. There was a highly significant
statistical difference in FEV1% of predicted associated with the distribution 
of TGF-β1 gene genotypes: 56.9 ±8.4% with Pro-Leu genotype and 35.5 ±8.8%
with Leu-Leu genotype in COPD patients, 93.2 ±6.2% with Pro-Leu genotype
and 86.7 ±0.9% with Leu-Leu genotype in the resistant smokers group.
C Co on nc cl lu us si io on ns s: :   The Pro-allele genotype is associated with increased production
of TGF-β1, which has a protective role against the development of COPD and is
important in preserving the decline of FEV1 in COPD patients.
K Ke ey y   w wo or rd ds s: :   chronic obstructive pulmonary disease, leucine, proline domains.
Introduction
Chronic obstructive pulmonary disease (COPD) is one of the leading
causes of death worldwide. It has been estimated that COPD will become
the third leading cause of mortality in the world by the year 2020 [1].
Although cigarette smoking is the main environmental risk factor for
developing COPD, only about 15% of smokers develop clinically significant
disease, suggesting that there are other influences on disease expression.
It was estimated that smoking contributes 15% to the variability of lung
function, while genetic factors account for a further 40% [2].
Maccloskey et al. [3] suggested an interaction between genetic and
environmental influences. Moreover, a study was done in the Chest
Department, Cairo University in collaboration with Tsukuba University
Hospital in Japan, to assess the association of CLCA1 gene polymorphisms
with COPD in Japanese and Egyptian populations; the distributions tended
to show a significant difference in the Egyptian and the Japanese groups.
It seems likely that different ethnic populations have different components
of COPD. This may be one of the reasons why prevalence of risk alleles of
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candidate genes for COPD differs greatly between
different studies analyzing different ethnic groups
[4]. On the other hand, Yoon et al. [5] could not
identify significant associations between trans-
forming growth factor β1 genetic polymorphisms
and COPD among Koreans as reported previously
in Caucasians, reflecting racial differences in the
pathogenesis of COPD.
The genetic polymorphisms that have been
identified, such as α1-antitrypsin deficiency, only
account for 1-2% of COPD cases [6]. A variety of
candidate genes have been assessed using case
control association studies such as microsomal
epoxide hydrolase, glutathione S-transferase and
α1 antichymotrypsin [7].
The TGF-β1 gene is one of the genes having 
a number of actions that make it a candidate for 
a role in the pathogenesis of COPD. TGF-β1 is 
a cytokine with many different effects on cell
proliferation, differentiation and inflammation.
Some of these actions could protect against the
development of COPD [8].
TGF-β1 can inhibit matrix metalloproteinase,
which  may  contribute  to  the  development  of
emphysema through the digestion of elastic fibres
[9]  and  was  found  to  be  associated  with  the
emphysema phenotype in the Japanese population
[10]. It also promotes the formation of elastin and
this could help repair damage to the lungs of
individuals who are at risk of developing COPD [11].
The aim of this work is to detect the association
between TGF-β1 genotypes and susceptibility to
developing chronic obstructive pulmonary diseases.
Material and methods
This  study  was  performed  in  Ain  Shams
University, Chest Department and Chest Outpatient
Clinic and Pulmonary Function Unit in the National
Research Centre, Cairo. Seventy male subjects were
included; age range was between 54 and 60 years.
They were divided into group 1 which included 25
smokers with COPD, group 2 including 25 smokers
who did not develop COPD proved clinically and by
normal spirometry (resistant smokers), and group
3 including 20 apparently normal non-smokers, with
normal spirometry, as a control group. They were
subjected to full medical history taking, clinical
examination, plain chest X-ray postero-anterior view,
pre- and post-bronchodilator spirometric measure-
ments of FEV1 (forced expiratory volume in the first
second),  FEV1/FVC  (forced  vital  capacity)  and
identification of TGF-β1 genotypes in serum. All
patients gave written informed consent, having
obtained approval from the ethical commission. The
patients were assigned to the study according to
one or more of the following criteria:
• age above 50 years,
• smoking history above 20 pack years,
• clinical and radiological examination fulfilled the
diagnostic criteria of COPD [12],
• staging of COPD was based on the criteria defined
by GOLD [13],
• normal  pulmonary  function  test  (PFT)  was
considered as FEV1 > 85% and FEV1/FVC > 70% of
predicted,
• bronchodilators stopped 24 h before PFT,
• none of the patients was on current systemic
corticosteroid therapy,
• no other diseases were present other than COPD,
• none of the patients was working in industrial
areas.
D De et te ec ct ti io on n   o of f   s se er ru um m   T TG GF F- -β β1 1 g ge en ne e   
S Sa am mp pl li in ng g
Blood  samples  were  collected  using  EDTA-
containing blood tubes and treated with sucrose
lysis buffer and a nuclear cell pellet stored at –80°C
until DNA extraction.
D DN NA A   e ex xt tr ra ac ct ti io on n   f fr ro om m   2 20 00 0   µ µl l   w wh ho ol le e   b bl lo oo od d
Genomic DNA was extracted using a Qiagen kit
following  standard  protocols  given  by  the
manufacturer.
P Po ol ly ym me er ra as se e   c ch ha ai in n   r re ea ac ct ti io on n   ( (P PC CR R) )
Reaction  mixtures  of  50  µl  were prepared
containing 2 µl DNA, 3 µl Taq polymerase (1U taq
polymerase) [Bioflux], 5 µl dNTPs (2.5 mM each)
[Bioflux], 10 µl of each primer, 5 ﾵl PCR buffer
(10X), 5 µl MgCl2 (15 mM MgCl2) and 10 µl distilled
water.
The  forward  primer  sequence  was
ACCACACCAGCCCTGTTCGC and the reverse primer
sequence was AGTAGCCACAGCAGCGGTAGCAGCT-GC
[14], using a thermocycler (T1 Thermocycler 96,
Biometra GmbH, Göttingen, Germany). PCR was
performed with an initial denaturation at 94°C for
3 min. This was followed by 33 cycles with de-
naturation at 94°C for 50 s, annealing at 66°C for 
1 min, then elongation at 72°C for 1 min, and a final
elongation of 10 min at 72°C.
R Re es st tr ri ic ct ti io on n    e en nz zy ym me e    f fr ra ag gm me en nt t    l le en ng gt th h
p po ol ly ym mo or rp ph hi is sm m   ( (R RF FL LP P) )
6 µl of the amplification product was digested
with 4 µl PstI restriction endonuclease enzyme
(Roche Diagnostics, Hague Road, IN, USA) in a 24 µl
volume  mixture  containing:  0.4  µl  restriction
enzyme, 2 µl Sure/Cut Buffer H, 0.2 µl BSA, 15.4 µl
distilled water and 6 µl amplification product. The
reaction mixture was inoculated at 37°C for 1 h.
Restriction enzyme digestion PCR products were
subjected to electrophoresis in a 2.5% agarose gel
at 120 mV for 2 h in TBE buffer.Arch Med Sci 1, February / 2010 73
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Using ultraviolet transillumination after ethidium
bromide  staining,  the  products  (123  bp)  were
visualized  and  the  size  of  the  product  was
determined using 123 bp ladder (Figure 1). 
S St ta at ti is st ti ic ca al l   a an na al ly ys si is s
SPSS statistical software package (V. 15.2, Echo
soft Corp., USA, 2006) was used for data analysis.
Data were expressed as mean ± SD for quantitative
measures and both number and percentage for
categorical data. Student’s t test was used for
comparison  between  two  independent  mean
groups for parametric data and ˇ2 test to study the
association between each 2 variables or comparison
between 2 independent groups. The probability of
error at 0.05 was considered as significant and error
at 0.01 and 0.001 as highly significant. Calculated
relative risk assessments (calculated odds ratio, OR)
measured the level risk among diseased individuals
compared  to  non-diseased  ones.  They  were
calculated as absolute figures and as a standard
error of estimate (95%).
Results
Seventy male subjects were enrolled in the study.
The age and the smoking history were matched
between groups (p > 0.05). There was a highly
statistically significant decrease in the mean value
of the post-bronchodilator FEV1 % of predicted in
group 1 (COPD), 41.5%, compared to that of group 2
(resistant smokers), 92.2%, and of group 3 (control),
92.6%  (p <  0.001).  There  was  no  statistically
significant difference in the mean value of the post-
bronchodilator FEV1 % of predicted between groups
2 and 3 (p > 0.05) (Table I). The distribution of the
genotypes of the TGF-β1 gene in the studied groups
is shown in Figure 2. The proline-proline (Pro-Pro)
genotype was not detected in the study. There was
a highly statistically significant increase of the
leucine-leucine (Leu-Leu) genotypes distribution in
group 1, 72% of COPD cases, compared to group 2,
16% of resistant smokers, and group 3, 15% of
controls, p < 0.001. There was no statistically
significant difference between group 2 and group
3 in the genotype distribution of the TGF-β1 gene.
There was a highly statistically significant reduction
in the mean value of the post-bronchodilator FEV1 %
of predicted in the case of Leu-Leu genotypes
compared to that in the case of Pro-Leu genotypes
in group 1 (COPD), 35.5 and 56.9% respectively 
(p < 0.001) and that in group 2 (resistant smokers),
86.7 and 93.2% respectively (p < 0.001). There was
no statistically significant difference of mean value
of the post-bronchodilator FEV1 % of predicted in
group  3  (control)  according  to  the  genotype
distribution (p > 0.05) (Table II). There was a highly
statistically significant difference between the
distributions of TGF-β1 gene genotypes in group 1
(COPD) according to the stages of COPD. From 
7 cases with the Pro-Leu genotype, 5 (71.4%) were
in stage II and 2 (28.6%) in stage III, compared to
one case from 18 (5.5%) with the Leu-Leu genotype
in stage II, 12 (66.7%) in stage III and 5 (27.7%) in
F Fi ig gu ur re e    1 1. . Agarose  gel  showing  RFLP  for  TGF-β1
genotypes at codon 10. Lane 1 shows 123 bp DNA
ladder lanes 1, 2, 3, 4, 5, 6 and 9 show Leu-Leu
genotype and lanes 7, 8, 10 and 11 show Pro-Leu
genotype
G Gr ro ou up p    N N° ° M Me ea an n    M Me ea an n    M Me ea an n   p po os st t- -
a ag ge e s sm mo ok ki in ng g b br ro on nc ch ho od di il la at to or r
± ±   S SD D   [ [y ye ea ar r] ] h hi is st to or ry y   ± ±   S SD D F FE EV V1 1   % %   o of f
p pr re ed di ic ct te ed d   ± ±   S SD D
1 25 57.28 ±1.99 50 ±6.8 41.5 ±13
2 25 57.32 ±1.46 48.72 ±8.57 92.2 ±6.1
3 25 56.95 ±1.63 – 92.6 ±6.2
1 vs. 2 T –0.081 0.585 –17.56
P > 0.05 > 0.05 < 0.001
1 vs. 3 T 0.598 – –17.31
P > 0.05 – < 0.001
2 vs. 3 T 0.802 – –0.24
P > 0.05 – > 0.05
T Ta ab bl le e   I I. .   Statistically significant difference of the mean
values of age (years), smoking history (pack years) and
percent of predicted FEV1 post-bronchodilator between
the 3 groups74 Arch Med Sci 1, February / 2010
stage IV (p < 0.01) (Table III). Smokers with the Pro-
Leu allele are at low risk of developing COPD (OR < 1)
while smokers with Leu-Leu allele are at high risk
of developing COPD (OR > 1) (Table IV). 
Discussion
TGF-β1 can inhibit matrix metalloproteinase,
which  may  contribute  to  the  development  of
emphysema through the digestion of elastic fibres.
It also promotes the formation of elastin and this
could help repair damage to the lungs of individuals
who are smokers and who are at risk of developing
COPD.  TGF-β1  plays  a  role  in  maintaining  the
integrity of the pulmonary vasculature [11].
Alveolar  macrophages  from  COPD  patients
release less TGF-β1 than smokers with normal lung
function and non-smokers, which may reduce the
anti-inflammatory and anti-elastolytic responses in
COPD  patients,  subsequently  contributing  to
progressive extracellular matrix destruction [15]. 
This study selected randomized samples of
subjects of the same sex and race. The mean ages
of the subjects and their smoking index were
statistically matched (Table I). All subjects were of
Caucasian origin; it was found that the frequency
of an allele can vary in different racial groups and
that  the  Pro  allele  of  the  TGF-β1 gene  was
significantly more common in African Americans
than in white subjects [16].
This  study  included  patients  with  a  heavy
smoking history of more than 20 pack years [17].
Several  studies  [14,  18]  have  detected  TGF-β1
genotype and increased susceptibility to COPD in
subjects with mean smoking index of 45 pack
years, which is nearly equal to the smoking index
of the studied subjects, ± 50 pack years (Table I).
Three genotypes have been demonstrated for
the TGF-β1 gene: Pro-Pro, Pro-Leu and Leu-Leu [14].
In our study the Pro-Pro genotype was not detected.
This may be explained by the racial differences in
the frequency of the Pro allele [16, 19].
In the COPD patients (group 1), the incidence of
the Pro-Leu allele of TGF-β1 was low (28% of the
total number of COPD cases). This result agreed
with that of Wu et al. [14] who detected the Pro
allele in 33% of COPD cases. There was a highly
statistically significant increase in the percent of
cases with the Pro-Leu allele in group 2 (resistant
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G Gr ro ou up ps s G Ge en no ot ty yp pe es s    M Me ea an n   ± ±   S SD D   o of f    T T P P
o of f p po os st t- -b br ro on nc ch ho od di il la at to or r    v va al lu ue e v va al lu ue e
T TG GF F- -β β1 1 g ge en ne e F FE EV V1 1 % %   o of f   p pr re ed di ic ct te ed d
Pro-Leu 56.9 ±8.4
COPD N = 7 (28%)
5.61 < 0.001
N = 25 Leu-Leu 35.5 ±8.8
N = 18 (72%)
Resistant
Pro-Leu  93.2 ±6.2
smokers
N = 21 (84%)
4.5 < 0.001
N = 25 Leu-Leu 86.7 ±0.9
N = 4 (16%)
Pro-Leu 92.8 ±6.5
Control N = 17 (85%)
0.4 > 0.05
N = 20 Leu-Leu 91.6 ±4.1
N = 3 (15%)
T Ta ab bl le e   I II I. .   Statistically significant difference of mean value
of post-bronchodilator FEV1 % of predicted in each of
the studied groups according to the distribution of 
TGF-β1 genotypes
G Gr ro ou up p   1 1   ( (C CO OP PD D) ) G Ge en ne et ti ic c   p po ol ly ym mo or rp ph hi is sm m   
o of f   T TG GF F- -β β1 1 g ge en ne e
X
2 = 12.63
P Pr ro o- -L Le eu u L Le eu u- -L Le eu u
N No o. .   = =   7 7 N No o. .   = =   1 18 8
Stage II No. 51
% 71.4 5.5
Stage III No. 2 12
% 28.6 66.7 p < 0.01
Stage IV No. 05
%0 27.7
T Ta ab bl le e   I II II I. .   Statistically significant difference of the
distribution of TGF-β1 genotypes in group 1 (COPD)
according to COPD stages
V Va al lu ue e 9 95 5% %   c co on nf fi id de en nc ce e   i in nt te er rv va al l
L Lo ow we er r U Up pp pe er r
F Fo or r   c co oh ho or rt t 0.333 0.174 0.639
P Pr ro o- -L Le eu u
F Fo or r   c co oh ho or rt t 4.5 1.77 11.41
L Le eu u- -L Le eu u
N Nu um mb be er r   o of f 50
v va al li id d   c ca as se es s
T Ta ab bl le e   I IV V. .   Calculated odds ratio between Pro-Leu and
Leu-Leu genotypes of TGF-β1 gene in group 1 (COPD)
and group 2 (resistant smokers)
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smokers) and group 3 (control) compared to group 1,
84, 85 and 28% respectively, p < 0.001 (Figure 2).
On  the  other  hand,  there  was  no  statistically
significant  difference  in  the  incidence  of  the 
Pro-Leu allele between groups 2 and 3, p > 0.05 
(Table IV). These findings agreed with other studies
which reported that the frequency of the Pro allele
is lower in COPD cases than in resistant smokers
and control subjects [14, 20]. However, a study done
on 36 patients with COPD, 27 resistant smokers and
60 healthy non-smokers with normal pulmonary
function did not find any statistically significant
differences in the distribution of genotypes of the
TGF-β1 gene between the three studied groups and
did not demonstrate a role of the TGF-β1 genotypes
in COPD [21].
The results of our study showed that there were
7 cases with the Pro allele in the COPD group. The
mean value of the percent of predicted FEV1 of
these 7 cases was statistically higher (56.9 ±8.4%)
compared to that of the other 18 cases of COPD
with  Leu-Leu  genotype  (35.5  ±8.8%)  p <  0.01 
(Table II). This may be attributed to the protective
role of the Pro allele against further decline in FEV1,
which is in concordance with 2 studies on patients
with cystic fibrosis [22] and on 590 smokers [23].
Moreover,  the  relation  between  genetic
polymorphism of the TGF-β1 gene and the stages
of COPD [13] were studied in group 1. There were 
7 cases with Pro-Leu genotype; 5 cases were in
stage II COPD and 2 cases in stage III. There were
18 cases with Leu-Leu genotype: one case in stage II,
12 in stage III and 5 in stage IV (Table III). These
results demonstrated that the Pro allele of the TGF-β1
gene has a protective effect on the lung function
of COPD cases and decreases the rapid decline of
FEV1, in agreement with other studies [22, 23].
In group 2, resistant smokers, the mean value of
the percent of predicted FEV1 in subjects with Pro-
Leu genotype (21 cases) was 93.2 ±6.2%, and 86.7
±0.9%  in  the  subjects  with  Leu-Leu  genotype 
(4 cases) p > 0.05 (Table II). In spite of the presence
of Leu-Leu genotype (4 cases) in this group, the
mean value of the FEV1 percent of predicted was
still  within  the  normal  range  but  statistically
significantly lower than that of the subjects with
Pro-Leu genotype (21 cases), p < 0.001. This may be
attributed to other genetic factors which protect
against COPD in resistant smokers. These results
agreed with those of Arkwright et al. [22], who
concluded that the Pro allele has a protective effect
on lung function and decreases the rapid decline
of FEV1.
The calculated odds ratio (OR) showed a low risk
of developing COPD in smokers with the Pro-Leu
allele (OR = 0.33), and a high risk of developing
COPD in smokers with the Leu-Leu allele, while
smokers with the Leu-Leu allele are at high risk of
developing COPD (OR = 4.5) (Table IV).
This result was in parallel to that found by Wu
et al. [14],who observed that the Pro allele occurred
less frequently in subjects with COPD than in
resistant smokers, and the OR was 0.59 for smokers
with the Pro allele and 3.2 for smokers with the Leu
allele.
In spite of the limited number of patients, this
case  control  study  gave  an  idea  about  the
distribution of TGF-β1 genotypes in Egyptians and
demonstrated its protective role in COPD. Moreover,
absence of the Pro-Pro allele in all cases of the
study denotes high predisposition to COPD in
Egyptian smokers.
In conclusion, although cigarette smoking is the
primary risk factor in COPD, genetic risk factors
likely influence its development. Moreover, the
proline allele of the TGF-β1 gene is expressed more
commonly in resistant smokers than in smokers
who develop COPD, demonstrating a protective role
against COPD and an important effect in preserving
further decline in FEV1. 
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